AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of advanced RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of advanced RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody, in Phase I and Phase II clinical trials in squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AVEO
CUSIP05358810
Phone617-588-1960
Debt
Debt-to-Equity Ratio-0.36
Current Ratio1.34
Quick Ratio1.34
Price-To-Earnings
Trailing P/E Ratio-15.00
Forward P/E Ratio-8.89
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.58 million
Price / Sales37.64
Cash FlowN/A
Price / CashN/A
Book Value($0.34) per share
Price / Book-7.06
Profitability
EPS (Most Recent Fiscal Year)($0.16)
Net Income$-65,020,000.00
Net Margins-1,073.16%
Return on EquityN/A
Return on Assets-39.88%
Miscellaneous
Employees19
Outstanding Shares118,870,000
AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions
What is AVEO Pharmaceuticals' stock symbol?
AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."
How were AVEO Pharmaceuticals' earnings last quarter?
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) released its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.00. The biopharmaceutical company had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.98 million. View AVEO Pharmaceuticals' Earnings History.
What price target have analysts set for AVEO?
4 equities research analysts have issued 12-month target prices for AVEO Pharmaceuticals' shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $4.1667 in the next year. View Analyst Ratings for AVEO Pharmaceuticals.
Are investors shorting AVEO Pharmaceuticals?
AVEO Pharmaceuticals saw a decline in short interest in the month of May. As of May 31st, there was short interest totalling 9,463,510 shares, a decline of 12.6% from the May 15th total of 10,822,613 shares. Based on an average daily volume of 1,300,305 shares, the short-interest ratio is currently 7.3 days. Approximately 9.9% of the company's stock are short sold. View AVEO Pharmaceuticals' Current Options Chain.
Who are some of AVEO Pharmaceuticals' key competitors?
Some companies that are related to AVEO Pharmaceuticals include TG Therapeutics Inc common stock (TGTX), Epizyme (EPZM), Wave Life Sciences (WVE), Reata Pharmaceuticals (RETA), Esperion Therapeutics (ESPR), Flexion Therapeutics (FLXN), Intra-Cellular Therapies (ITCI), Dynavax Technologies (DVAX), Vanda Pharmaceuticals (VNDA), Endocyte (ECYT), CytomX Therapeutics (CTMX), MacroGenics (MGNX), OptiNose (OPTN), Assembly Biosciences (ASMB) and Karyopharm Therapeutics (KPTI).
Who are AVEO Pharmaceuticals' key executives?
AVEO Pharmaceuticals' management team includes the folowing people:
- Mr. Michael P. Bailey, CEO, Pres & Director (Age 53)
- Mr. Matthew D. Dallas, Chief Financial Officer (Age 43)
- Dr. Michael N. Needle M.D., Chief Medical Officer (Age 58)
- Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance
- Dr. Emile Farhan Ph.D., VP of Technical Operations
Has AVEO Pharmaceuticals been receiving favorable news coverage?
News coverage about AVEO stock has been trending somewhat positive on Monday, according to Accern Sentiment. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. AVEO Pharmaceuticals earned a news impact score of 0.22 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 47.45 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are AVEO Pharmaceuticals' major shareholders?
AVEO Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include venBio Select Advisor LLC (2.72%), Point72 Asset Management L.P. (0.79%), Tibra Equities Europe Ltd (0.22%), X Square Capital LLC (0.19%), Spark Investment Management LLC (0.14%) and Element Capital Management LLC (0.11%). Company insiders that own AVEO Pharmaceuticals stock include Equity Opportunities Iv Growth, Peter J Barris and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals.
Which institutional investors are selling AVEO Pharmaceuticals stock?
Which institutional investors are buying AVEO Pharmaceuticals stock?
AVEO stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Tibra Equities Europe Ltd, Element Capital Management LLC, Birchview Capital LP, Verition Fund Management LLC and X Square Capital LLC. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Equity Opportunities Iv Growth, Peter J Barris and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals.
How do I buy shares of AVEO Pharmaceuticals?
Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AVEO Pharmaceuticals' stock price today?
One share of AVEO stock can currently be purchased for approximately $2.40.
How big of a company is AVEO Pharmaceuticals?
AVEO Pharmaceuticals has a market capitalization of $273.39 million and generates $7.58 million in revenue each year. The biopharmaceutical company earns $-65,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. AVEO Pharmaceuticals employs 19 workers across the globe.
How can I contact AVEO Pharmaceuticals?
AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]
MarketBeat Community Rating for AVEO Pharmaceuticals (AVEO)
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
